2022年度胃癌治疗进展  

Annual progress in the treatment of gastric cancer in 2022

作　　者：谢通 王雅坤[1] 沈琳[1] Xie Tong;Wang Yakun;Shen Lin(Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《肿瘤综合治疗电子杂志》2023年第1期1-6,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

摘　　要：2022年度胃癌治疗进展继续围绕精准靶向、免疫治疗展开。除程序性死亡蛋白-1(programmed death protein-1,PD-1)抑制剂继续确认其在一线治疗中的作用与地位外,双免治疗和新型的疗效预测标志物的探索也进一步深入。同时,抗人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)治疗与免疫治疗的联合前移至一线,新型的药物和联合治疗方式也开始斩获新的数据,如何达到“去化疗”成为HER-2阳性胃癌领域的下一目标。其他特殊人群例如Claudin 18.2、成纤维细胞生长因子受体(fibroblast growth factor receptor,FGFR)等,也都开始崭露头角。整体而言,2022年胃癌临床治疗朝着更加精准的方向前进。The progress in gastric cancer still focused on the precisive immunotherapy and target therapy in 2022.Except the confirmation of success in programmed death protein-1(PD-1)inhibitors,dual immunotherapy and novel biomarkers have been investigated too.Meantime,the combination of immunotherapy and anti-human epidermal growth factor receptor-2(HER-2)target therapy moved forward into first-line setting.New drugs and combination achieved more data,chemo-free become a new goal for HER-2 positive gastric cancer treatment.Other special population,such as Claudin 18.2 or fibroblast growth factor receptor(FGFR)positive gastric cancer also exhibited promising progress.Allover,the clinical treatment of gastric cancer moved forward precisively in 2022.

关 键 词：胃癌 年度进展 免疫治疗 精准治疗 

分 类 号：R735.2[医药卫生—肿瘤]